Photo of Kris Kappel

Kris Kappel

As co-vice-chair of the firm’s Intellectual Property practice specialty center, Kris counsels clients on how to manage and protect their intellectual property and data and use their IP assets strategically.

Follow:Read more about Kris KappelKris's Linkedin Profile
Blog SeriesConference Post (1)

This is the second in a series of articles designed to provide SXSW and LSI USA ’26 attendees and other MedTech professionals with practical considerations for efficiently executing mission-critical life science deals.

Collaborations often start with a simple premise: build something together, share the risk, and create value.

The complexity shows up later when investors or buyers ask who actually owns the platform.

In co-development structures involving devices and software, ownership and control are rarely binary. They are defined by layered licensing arrangements, regulatory allocations, manufacturing dependencies, and IP assignments that were often negotiated quickly to get a deal done.

This post is the second in our three-part series, Gearing Up for HTLH USA 2025, where our team of attorneys will share insights on intellectual property, equity, and exit strategies and how these issues intersect in the transactional context.

The healthcare industry is undergoing a rapid transformation, with startups driving innovation in patient care, diagnostics, data management, and telemedicine.

In today’s rapidly evolving healthcare industry, startup companies face significant hurdles in bringing innovative solutions to market. Licensing software and intellectual property provides a practical pathway for startups to overcome high development costs, regulatory complexities, and the need for advanced technology. By understanding various licensing models and the strategic importance of partnerships, healthcare startups can accelerate growth while ensuring compliance and security. This guide aims to empower entrepreneurs with the knowledge needed to make informed decisions about licensing, ultimately supporting innovation and better patient outcomes.

Patients' privacy and confidentiality concept.

Listen to Husch Blackwell’s Technology Transfer Attorneys Kris Kappel, Dill Myers, and Liam Reilly provide tips for “Winning” the Technology Agreement Tug of War.  This webinar reviews the most negotiated legal terms in Information Technology and Technology Agreements, including warranties, indemnification, and limitation of liabilities. This session also covers issues from both the…

3D printing continues to transform the medical field. Recently, doctors in Spain produced the world’s first 3D-printed rib cage and sternum, which is made entirely of titanium. The doctors surgically implanted the metal rib cage and sternum in a cancer patient. Last month, the FDA approved the first 3D-printed drug. The drug, which Aprecia Pharmaceuticals has named Spritam, is for treating patients with epilepsy. Aprecia Pharmaceuticals’ ZipDose® Technology utilizes 3D printing that overlays multiple layers of powdered medication on top of one another until the correct dosage is reached. This type of technology can lead to easier-to-take medication that is individualized in nature with precise dosages based on a patient’s needs.